Vinge advised Strax on an automatic redemption procedure

Vinge has advised Strax AB in connection with an automatic redemption procedure according to which each outstanding share in Strax has been split into two shares, of which one share (called redemption share) has been redeemed for a proceed of SEK 1.10.

Vinge advises Oncopeptides in connection with a directed share issue

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 546 million, before issue costs.

Vinge has advised Cavotec SA in connection with rights issue

Cavotec SA (Nasdaq Stockholm) has completed a rights issue of shares, whereby Cavotec SA raised proceeds of MSEK 204, before issue costs.

Vinge advises Fagerhult

AB Fagerhult (publ) has entered into an agreement to acquire iGuzzini illuminazione S.p.A. for EUR 385 million on a cash and debt free basis.

Vinge advises in connection with the sale of preference shares in Volvo Cars

Vinge has advised the Första AP fonden in connection with the sale of all of Första AP fonden’s preference shares in Volvo Cars.

Vinge is advising Danica Pension, Livsforsikringsaktieselskab, part of Danske Bank Group, in connection with the sale of all of shares in Danske Pension Försäkringsaktiebolag (publ).

Danica Pension Försäkringsaktiebolag (publ) has approx. 60 employees, 150,000 personal customers and 15,000 business customers.

Vinge advises Azelio in connection with its capital raising and listing on Nasdaq First North

Vinge has advised Azelio AB (publ) (“Azelio”) in connection with its capital raising and listing on Nasdaq First North.

Vinge advises Xspray Pharma in connection with a directed share issue

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Vinge advises Biotage in connection with its acquisition of PhyNexus

Vinge advises Biotage AB (publ) (“Biotage”), listed on Nasdaq Stockholm, in connection with its acquisition of PhyNexus, Inc. (“PhyNexus”), financed through a combination of newly issued shares and existing cash at hand.

Vinge assists Stendörren in connection with EQT Real Estate II’s cash offer to the shareholders in Stendörren

Vinge has assisted Stendörren Fastigheter AB (publ) (“Stendörren”) in connection with EQT Real Estate II’s, through Chicago Holding AB (“Chicago Holding”), cash offer to the shareholders in Stendörren.

Vinge advises Vicore Pharma in connection with a directed share issue

The board of directors of Vicore Pharma has resolved, subject to the approval by an extraordinary general meeting, on a directed new issue of shares, whereby Vicore Pharma will raise proceeds of approximately SEK 160 million before issue costs. 

Vinge assists Vostok New Ventures Ltd in connection with an investment in Voi

Vinge has assisted Vostok New Ventures Ltd (“Vostok”) in connection with an investment by a number of investors in Voi Technology AB, a company that provides an electric scooter sharing service.

Vinge advised Equinor in connection with its investment in Medfield Diagnostics

Vinge advised Equinor Technology Ventures AS (”Equinor”) in connection with its acquisition in Medfield Diagnostics Aktiebolag (publ) (“Medfield”).

Vinge advises Investor and the Knut and Alice Wallenberg Foundation in connection with Saab’s rights offering

Saab AB is carrying out a rights offering of SEK 6 billion.

Vinge advises Hansa Medical in connection with a directed share issue

The board of directors of Hansa Medical has resolved on a directed new issue of shares, whereby Hansa Medical will raise proceeds of approximately SEK 453 / USD 50 million, before issue costs.